ERB-041 ( DrugBank: - )

---

3 diseases

ID	Disease name (Link within this page)	Number of trials
46	Malignant rheumatoid arthritis	4
96	Crohn disease	1
226	Interstitial cystitis with Hunners ulcer	1

46. Malignant rheumatoid arthritis

---

Clinical trials : 4,356 /  Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2005-001319-23-IT (EUCTR)	21/10/2005	30/09/2005	A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 3 Oral Doses of ERB-041 in Subjects With Rheumatoid Arthritis on a Background of Methotrexate Therapy	A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 3 Oral Doses of ERB-041 in Subjects With Rheumatoid Arthritis on a Background of Methotrexate Therapy	Rheumatoid arthritis MedDRA version: 6.1;Level: PT;Classification code 10039073	Product Name: ERB-041 Product Code: ERB-041 Other descriptive name: NA Product Name: ERB-041 Product Code: ERB-041 Other descriptive name: NA Product Name: ERB-041 Product Code: ERB-041 Other descriptive name: NA	WYETH LEDERLE	NULL	Not Recruiting			Female: yes Male: yes			Hungary;Spain;Italy
2	EUCTR2005-001319-23-ES (EUCTR)	14/10/2005	22/06/2005	A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 3 Oral Doses of ERB-041 in Subjects With Rheumatoid Arthritis on a Background of Methotrexate Therapy.Estudio aleatorizado, de grupos paralelos, en doble ciego y controlado con placebo, dirigido a evaluar la eficacia y la seguridad de 3 dosis orales distintas de ERB-041 en sujetos con artritis reumatoide en tratamiento de fondo con metotrexato	A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 3 Oral Doses of ERB-041 in Subjects With Rheumatoid Arthritis on a Background of Methotrexate Therapy.Estudio aleatorizado, de grupos paralelos, en doble ciego y controlado con placebo, dirigido a evaluar la eficacia y la seguridad de 3 dosis orales distintas de ERB-041 en sujetos con artritis reumatoide en tratamiento de fondo con metotrexato	Rheumatoid arthritis	Product Name: ERB-041 Product Code: ERB-041 Product Name: ERB-041 Product Code: ERB-041 Product Name: ERB-041 Product Code: ERB-041	Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical resaearch and Development	NULL	Not Recruiting			Female: yes Male: yes	260	Phase 2	Hungary;Spain;Italy
3	NCT00141830 (ClinicalTrials.gov)	August 2005	30/8/2005	Study Evaluating ERB-041 With Methotrexate in Rheumatoid Arthritis	A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 3 Oral Doses of ERB-041 in Subjects With Rheumatoid Arthritis on a Background of Methotrexate Therapy	Rheumatoid Arthritis	Drug: Methotrexate plus ERB-041 for 12 weeks;Drug: Placebo for 12 weeks	Wyeth is now a wholly owned subsidiary of Pfizer	NULL	Completed	18 Years	80 Years	All	159	Phase 2	United States;Canada;Hungary;Italy;Mexico;Spain
4	EUCTR2005-001319-23-HU (EUCTR)	22/07/2005	03/06/2005	A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 3 Oral Doses of ERB-041 in Subjects With Rheumatoid Arthritis on a Background of Methotrexate Therapy	A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 3 Oral Doses of ERB-041 in Subjects With Rheumatoid Arthritis on a Background of Methotrexate Therapy	Rheumatoid arthritis	Product Name: ERB-041 Product Code: ERB-041 INN or Proposed INN: Not available Product Name: ERB-041 Product Code: ERB-041 INN or Proposed INN: Not available Product Name: ERB-041 Product Code: ERB-041 INN or Proposed INN: Not available	Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical resaearch and Development	NULL	Not Recruiting			Female: yes Male: yes	260		Hungary;Spain;Italy

96. Crohn disease

---

Clinical trials : 2,442 /  Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00245947 (ClinicalTrials.gov)	April 2004	26/10/2005	Study Evaluating ERB-041 in Active Crohn's Disease	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel- Design, Exploratory Pharmacogenomic, Safety and Activity Study of Orally Administered ERB-041 in Subjects With Inflammation Associated With Active Crohn's Disease	Crohn's Disease	Drug: ERB-041	Wyeth is now a wholly owned subsidiary of Pfizer	NULL	Completed	18 Years	N/A	Both	22	Phase 1	NULL

226. Interstitial cystitis with Hunners ulcer

---

Clinical trials : 145 /  Drugs : 156 - (DrugBank : 51) / Drug target genes : 64 - Drug target pathways : 146

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00275379 (ClinicalTrials.gov)	August 2006	9/1/2006	Study Evaluating Orally Administered ERB-041 in Subjects With Active Interstitial Cystitis	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Exploratory Study of Orally Administered ERB-041 in Subjects With Active Interstitial Cystitis	Cystitis, Interstitial	Drug: ERB-041	Wyeth is now a wholly owned subsidiary of Pfizer	NULL	Withdrawn	18 Years	N/A	Female	0	N/A	United States;Austria;Germany

Back to top